Condition: Persistent Corneal Epithelial Defect · Sponsor: Glaukos Corporation
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
This description comes directly from the study's public registry record.
Study Director · 949-739-8749 · ClinicalResearch@Glaukos.com
Always discuss trial participation with your own doctor first.
| Glaukos Investigative Site | Dothan, Alabama, United States | Recruiting |
| Glaukos Investigative Site | Petaluma, California, United States | Recruiting |
| Glaukos Investigative Site | Torrance, California, United States | Recruiting |
| Glaukos Investigative Site | Colorado Springs, Colorado, United States | Recruiting |
| Glaukos Investigative Site | Grand Junction, Colorado, United States | Recruiting |
| Glaukos Investigative Site | Bradenton, Florida, United States | Recruiting |
| Glaukos Investigative Site | Fort Myers, Florida, United States | Recruiting |
| Glaukos Investigative Site | South Miami, Florida, United States | Recruiting |
| Glaukos Investigative Site | Atlanta, Georgia, United States | Recruiting |
| Glaukos Investigative Site | Carmel, Indiana, United States | Recruiting |
| Glaukos Investigative Site | Fraser, Michigan, United States | Recruiting |
| Glaukos Investigative Site | Kansas City, Missouri, United States | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05966493